Post-hoc analyses comparing the efficacy of rasagiline @mg/day ( n = @ ) versus placebo ( n = @ ) on key symptoms at @ weeks , and on total-UPDRS scores over @ weeks ( completer population : rasagiline @mg/day n = @ , placebo n = @ ) were performed .